View Older Stories View More Recent Stories

Aug 8, 2022 06:45AM Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Aug 8, 2022 06:45AM Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Aug 5, 2022 08:50PM Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Aug 5, 2022 08:50PM Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Jul 27, 2022 06:47AM BioNTech SE (BNTX) and Pfizer (PFE) Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
Jul 27, 2022 06:45AM Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
Jun 30, 2022 06:45AM Pfizer (PFE) Submits US NDA for PAXLOVID
Jun 30, 2022 06:45AM Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™
Jun 29, 2022 04:45PM Pfizer (PFE), BioNTech (BNTX) Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Jun 29, 2022 04:45PM Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Jun 29, 2022 04:45PM Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine
Jun 28, 2022 06:00AM Roivant (ROIV) and Pfizer (PFE) Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Jun 28, 2022 06:00AM Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Jun 28, 2022 06:00AM Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Jun 28, 2022 06:00AM Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Jun 27, 2022 05:58AM BioNTech SE (BNTX) and Pfizer (PFE) Report Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against
Jun 25, 2022 10:02AM Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Jun 25, 2022 10:00AM Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron
Jun 24, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts
Jun 23, 2022 11:45AM Valneva and Pfizer Announce Closing of Equity Investment
Jun 23, 2022 10:35AM Pfizer Declares Third-Quarter 2022 Dividend
Jun 21, 2022 06:11AM Valneva SE (VALN), Pfizer (PFE) Enter Equity Subscription Agreement and Update Terms of Collaboration
Jun 20, 2022 01:00AM Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Jun 20, 2022 01:00AM Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Jun 17, 2022 09:24AM Pfizer (PFE) and BioNTech (BNTX) COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Jun 17, 2022 09:24AM Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Jun 17, 2022 09:22AM Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age
Jun 17, 2022 06:46AM Myovant Sciences (MYOV) and Pfizer (PFE) Announce Publication of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Jun 17, 2022 06:45AM Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Jun 17, 2022 06:45AM Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Jun 14, 2022 04:31PM Pfizer (PFE) Reports Additional Data on PAXLOVID Supporting Upcoming NDA Submission to U.S. FDA
Jun 14, 2022 04:30PM Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA
Jun 13, 2022 04:01PM Pfizer (PFE), MorphoSys (MOR) and Incyte (INCY) Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Jun 13, 2022 04:01PM Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Jun 9, 2022 10:00AM Pfizer (PFE) Completes Acquisition of ReViral
Jun 9, 2022 10:00AM Pfizer Completes Acquisition of ReViral
Jun 9, 2022 09:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Jun 8, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Jun 6, 2022 11:01AM Pfizer (PFE) to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
Jun 6, 2022 11:00AM Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.
Jun 4, 2022 01:38PM Pfizer (PFE) Reports Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE
Jun 4, 2022 08:00AM Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer
Jun 2, 2022 06:51AM Myovant Sciences (MYOV), Pfizer (PFE) Announce FDA Acceptance of sNDA for MYFEMBREE®
Jun 2, 2022 06:50AM Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Jun 2, 2022 06:50AM Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
May 31, 2022 10:00AM Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability
May 26, 2022 06:46AM Pfizer (PFE) Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination
May 26, 2022 06:45AM Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
May 25, 2022 10:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
May 25, 2022 04:41AM Pfizer Launches 'An Accord for a Healthier World' to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries
View More Recent Stories View Older Stories